The Quantellect read.As of Nov 19, 2026, 7 active firms cover Surgery Partners Inc: 5 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $14.00 to $21.00, a moderate spread. The average target of $17.57 sits 35% below the current $26.97. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.02 next quarter toward $0.20 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy571%
Neutral229%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$17.57
-34.8% downside
Average target across 7 active firms as of Nov 19, 2026 vs $26.97 current
Highest Target$21.00
Average Target$17.57
Lowest Target$14.00
Detailed analyst forecasts for SGRY
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 5 of 7 active firms rate SGRY a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SGRY EPS & revenue forecast
EPS · NEXT QUARTER
$0.02
Range $0.02 – $0.02 · 1 analysts · -167% YoY
Next period, 1 analysts expect Surgery Partners Inc to earn $0.02 a share (range $0.02 – $0.02), versus $-0.03 a year earlier. Full-year consensus is $0.41, growing to $0.20 the year after.
REVENUE · NEXT QUARTER
$706.0M
Range $672.9M – $739.0M · 1 analysts · -13% YoY
Revenue is expected to reach $706.0M (range $672.9M – $739.0M), -12.9% year-over-year. Full-year consensus is $3.2B, rising to $2.9B next year.
Top analysts covering Surgery Partners Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SGRY.
#1
BS
Bill Sutherland
Benchmark · Rank #48
Buy
$24.00-11.0% to target
Overall win rate
46%
+ Follow
#2
Tao Qiu
Macquarie · Rank #126
Buy
$33.00+22.4% to target
Overall win rate
45%
+ Follow
#3
Ben Hendrix
RBC Capital · Rank #150
Buy
$19.00-29.6% to target
Overall win rate
44%
+ Follow
#4
Sarah James
Cantor Fitzgerald · Rank #159
Neutral
$23.50-12.9% to target
Overall win rate
37%
+ Follow
#5
Brian Tanquilut
Jefferies · Rank #280
Buy
$17.00-37.0% to target
Overall win rate
46%
+ Follow
SGRY stock forecast FAQ
What is SGRY's average 12-month price target?+
The 7 active firms with a live target average $17.57 for Surgery Partners Inc over the next 12 months, ranging from a $21.00 high to a $14.00 low, as of Nov 19, 2026.
Is SGRY stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SGRY?+
The Street-high target is $21.00 (UBS), and the Street-low is $14.00 (Barclays). The average of all 7 active-firm targets is $17.57.
How many active Wall Street firms cover SGRY?+
7 active firms have a recognized rating on Surgery Partners Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SGRY?+
Among analysts who currently cover SGRY, Bill Sutherland of Benchmark has the strongest overall Quantellect track record (Rank #48). Their current call is Buy with a $24.00 target.
What is Surgery Partners Inc's projected EPS for next quarter?+
The consensus estimate is $0.02 per share (range $0.02 – $0.02) across 1 analysts. Full-year EPS is projected at $0.41, rising to $0.20 the following year.
How much revenue is Surgery Partners Inc expected to report next quarter?+
Consensus revenue is $706.0M (range $672.9M – $739.0M). Full-year revenue is projected at $3.2B, growing to $2.9B next year.
Have analysts been upgrading or downgrading SGRY lately?+
As of Nov 19, 2026, 5 of 7 active firms rate SGRY a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SGRY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.